Factors influencing the efficacy of rilpivirine in HIV-1 subtype C in low- and middle-income countries | Zendy

Ujjwal Neogi | Zendy; Amanda Häggblom | Zendy; Kamalendra Singh | Zendy; Leonard C. Rogers | Zendy; Shwetha D. Rao | Zendy; Wondwossen Amogne | Zendy; Eugen Schülter | Zendy; Maurizio Zazzi | Zendy; Eddy Arnold | Zendy; Stefan G. Sarafianos | Zendy; Anders Sönnerborg | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Factors influencing the efficacy of rilpivirine in HIV-1 subtype C in low- and middle-income countries

Author(s) -

Ujjwal Neogi,

Amanda Häggblom,

Kamalendra Singh,

Leonard C. Rogers,

Shwetha D. Rao,

Wondwossen Amogne,

Eugen Schülter,

Maurizio Zazzi,

Eddy Arnold,

Stefan G. Sarafianos,

Anders Sönnerborg

Publication year - 2015

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkv359

Subject(s) - rilpivirine , low and middle income countries , medicine , human immunodeficiency virus (hiv) , low income , developing country , environmental health , virology , antiretroviral therapy , viral load , biology , socioeconomics , ecology , sociology

The use of the NNRTI rilpivirine in low- and middle-income countries (LMICs) is under debate. The main objective of this study was to provide further clinical insights and biochemical evidence on the usefulness of rilpivirine in LMICs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research